NOTICE
ANSM - Updated on: April 17, 2023
Drug Name
OROCAL VITAMIN D3 500 mg/400 IU, lozenge
Calcium/Cholecalciferol
Box
Please read this package insert carefully before taking this medication, as it contains important information for you.
You should always take this medicine exactly as described in this leaflet or as directed by your doctor or pharmacist.
· Keep this leaflet. You may need to read it again.
· Ask your pharmacist for advice or information.
· If you experience any side effects, tell your doctor or pharmacist. This also applies to any side effects not listed in this leaflet. See Section 4.
· You should contact your doctor if you do not feel any improvement or if you feel worse.
Keep this medicine out of the reach of children.
What is in this package insert?
1. What is OROCAL VITAMIN D3 500 mg/400 IU, lozenge, and what is it used for?
2. What should you know before taking OROCAL VITAMIN D3 500 mg/400 IU, lozenge?
3. How should you take OROCAL VITAMIN D3 500 mg/400 IU, lozenge?
4. What are the possible side effects?
5. How should OROCAL VITAMIN D3 500 mg/400 IU, lozenge be stored?
6. Package contents and other information.
1. WHAT IS OROCAL VITAMIN D3 500 mg/400 IU, lozenge, AND WHAT IS IT USED FOR?
Pharmacotherapeutic class - ATC code: vitamin D and calcium supplementation
(Medication affecting calcium balance. A: Digestive system and Metabolism).
This medication is indicated for adults in the following situations:
· in the elderly, in cases of calcium and vitamin D deficiency,
· in combination with osteoporosis treatments when calcium and vitamin D intake is insufficient.
2. WHAT INFORMATION SHOULD YOU KNOW BEFORE TAKING OROCAL VITAMIN D3 500 mg/400 IU, lozenge?
Never take OROCAL VITAMIN D3 500 mg/400 IU, lozenge:
· if you are allergic to calcium carbonate, cholecalciferol (vitamin D), or any of the other ingredients in this medication listed in Section 6;
· if you are immobilized for a prolonged period;
· if you have abnormally high levels of calcium in your blood (hypercalcemia);
· in cases of excessive calcium excretion in the urine (hypercalciuria);
· if you have too much vitamin D in your body (hypervitaminosis D);
· if you have kidney stones (calcium lithiasis).
IF IN DOUBT, IT IS ESSENTIAL TO CONSULT YOUR DOCTOR OR PHARMACIST.
Warnings and Precautions
Consult your doctor or pharmacist before taking OROCAL VITAMIN D3 500 mg/400 IU, lozenge:
Use this medication WITH CAUTION in the following cases:
· of long-term treatment, it is necessary to regularly monitor the amount of calcium excreted in the urine (calciuria), the amount of calcium in your blood (calcemia), and your kidney function. Depending on the results, your doctor may need to reduce or even discontinue your treatment;
· of additional high-dose calcium and vitamin D supplementation, which must be administered under strict medical supervision;
· of concomitant treatment with sodium fluoride or bisphosphonates; it is recommended to wait at least three hours between taking these medications and OROCAL VITAMIN D3;
· with concomitant treatment involving destramustine, thyroid hormones, strontium, or zinc; it is recommended to wait at least two hours between taking these medications and OROCAL VITAMIN D3;
· and in cases of treatment with a cycline-class antibiotic, it is recommended to take the antibiotic at least two hours before taking OROCAL VITAMIN D3 or 4 to 6 hours after taking OROCAL VITAMIN D3;
· of sarcoidosis or kidney failure;
· of immobility if you have osteoporosis.
IF IN DOUBT, DO NOT HESITATE TO ASK YOUR DOCTOR OR PHARMACIST FOR ADVICE.
Other Medications and OROCAL VITAMIN D3 500 mg/400 IU, lozenge
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications, especially digitalis, cyclines, bisphosphonates, estramustine, iron salts, thyroid hormones, strontium, zinc, thiazide diuretics, or lorlistat.
OROCAL VITAMIN D3 500 mg/400 IU, lozenge to be taken with food
The absorption of the calcium in this medication may be reduced by oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole grains). Do not take this medication within two hours of eating foods high in oxalic acid and phytic acid.
Pregnancy and Breastfeeding
If you are pregnant, do not exceed 1,500 mg of calcium and 600 IU of vitamin D3 per day: that is, one tablet per day.
If you are pregnant or breastfeeding, if you think you might be pregnant, or if you are planning a pregnancy, consult your doctor or pharmacist before taking this medication.
Driving and operating machinery
No specific effects.
OROCAL VITAMIN D3 500 mg/400 IU, chewable tablet contains isomalt and sucrose
This medication contains isomalt. Its use is not recommended in patients with fructose intolerance (a rare hereditary disorder).
This medication contains sucrose. Its use is not recommended in patients with fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase/isomaltase deficiency (rare hereditary disorders).
If your doctor has told you that you have an intolerance to certain sugars, contact them before taking this medication.
3. HOW TO TAKE OROCAL VITAMIN D3 500 mg/400 IU, lozenge?
Always take this medication exactly as described in this leaflet or as directed by your doctor or pharmacist. Check with your doctor or pharmacist if you have any questions.
Dosage
The dosage is 2 tablets per day.
IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR’S PRESCRIPTION.
Administration
FOR ADULTS ONLY.
Oral use.
The tablets are meant to be sucked.
Dosage Frequency
IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR’S PRESCRIPTION.
Duration of treatment
IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR’S PRESCRIPTION.
If you have taken more OROCAL VITAMIN D3 500 mg/400 IU, lozenge than you should have
If you take an excessive dose of OROCAL VITAMIN D3 500 mg/400 IU, lozenge, the following symptoms may occur: loss of appetite (anorexia), nausea, vomiting, intense thirst, increased urine output, constipation, abdominal pain, muscle weakness, fatigue, mental disturbances, bone pain, kidney stones, and, in severe cases, heart rhythm disturbances. An extreme increase in blood calcium levels can lead to coma or death.
If such effects occur, notify your doctor immediately so that he or she can take the necessary measures.
In the event of prolonged overdose, the kidneys may be irreversibly damaged, and calcifications may develop in the blood vessels or tissues.
If you forget to take OROCAL VITAMIN D3 500 mg/400 IU, lozenge
Do not take a double dose to make up for the dose you missed.
If you stop taking OROCAL VITAMIN D3 500 mg/400 IU, lozenge
Not applicable.
If you have any other questions about the use of this medication, ask your doctor or pharmacist for more information.
4. WHAT ARE THE POSSIBLE SIDE EFFECTS?
Like all medicines, this medicine can cause side effects, although not everyone gets them.
Uncommon (occurring in at least 1 in 1,000 and fewer than 1 in 100 treated patients)
· constipation,
· diarrhea,
· abdominal pain,
· bloating,
· nausea,
· skin rash,
· itching,
· hives.
Rare (occurring in at least 1 in 10,000 and in fewer than 1 in 1,000 treated patients)
· excessive increase in calcium levels in the blood or urine, in cases of prolonged treatment.
Very rare (occurring in fewer than 1 in 10,000 treated patients)
· allergic reactions, such as rapid swelling of the face and neck that may cause breathing difficulties (angioedema or laryngeal edema).
In patients with renal insufficiency, there is a risk of increased phosphate levels in the blood, the formation of kidney stones, or calcium deposits in the kidneys.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This also applies to any side effects not listed in this package insert. You can also report side effects directly through the national reporting system: the French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centers—Website: https://signalement.social-sante.gouv.fr/.
By reporting side effects, you help provide more information on the safety of this medication.
5. HOW SHOULD OROCAL VITAMIN D3 500 mg/400 IU, lozenge, BE STORED?
Keep this medication out of the sight and reach of children.
Do not use this medicine after the expiration date printed on the package. The expiration date refers to the last day of that month.
This medicine should be stored at a temperature not exceeding 25°C.
Keep the bottle tightly closed.
Do not dispose of any medication down the drain or with household trash. Ask your pharmacist how to dispose of medications you no longer use. These measures will help protect the environment.
6. PACKAGE CONTENTS AND OTHER INFORMATION
What OROCAL VITAMIN D3 500 mg/400 IU, lozenge contains
· The active ingredients are:
Calcium carbonate......................................................................................................... 1250 mg
Amount corresponding to elemental calcium ............................................................................ 500 mg
Cholecalciferol concentrate* ................................................................................................. 4 mg
Amount corresponding to VitaminD3................................................................................... 400 IU
For one chewable tablet.
*Composition of the cholecalciferol concentrate: cholecalciferol, DL-α-tocopherol, sucrose, modified food-grade starch, medium-chain triglycerides, sodium ascorbate, silicon dioxide.
· Other ingredients are: xylitol, povidone, magnesium stearate, sucralose, granulated lemon flavoring (isomalt (E 953), lemon flavoring, mono- and diglycerides of fatty acids).
What is OROCAL VITAMIN D3 500 mg/400 IU, lozenge, and outer packaging contents
This medication comes in the form of a lozenge. Box of 20, 30, 50, 60, 90, 100, 120, or 180.
Marketing Authorization Holder
ARROW GENERICS
26 Avenue Tony Garnier
69007 LYON
Marketing Authorization Holder
ARROW GENERIQUES
26 Avenue Tony Garnier
69007 LYON
Manufacturer
ASKER CONTRACT MANUFACTURING AS
DRAMMENSVEIEN 852
1383 ASKER
NORWAY
OR
TJOAPACK NETHERLANDS B.V.
Nieuwe Donk 9
4879 AC ETTEN-LEUR
NETHERLANDS
Drug names in the Member States of the European Economic Area
Not applicable.
The date this package insert was last revised is
[to be completed later by the marketing authorization holder]
Other
Detailed information about this medication is available on the ANSM (France) website.